Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights
Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights
Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights
Published on 15 November 2022 .Views 17.Comments 0